Clinical trials: Post-transplant Lymphoproliferative Disease
Hematopoietic Cell Transplantation Recipient, Plasma Cell Myeloma
Ixazomib Citrate and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma
This phase II trial studies how well ixazomib citrate and lenalidomide after stem cell transplant work in treating patients with newly diagnosed multiple myeloma.
- Trial name
- NCT01718743
- Testing
- Ixazomib Citrate, Lenalidomide, Questionnaire Administration
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- M.D. Anderson Cancer Center
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder
RATIONALE: Cyclosporine eye drops may prevent graft-versus-host disease of the eye in patients who have undergone donor stem cell transplant for hematologic cancer or bone marrow failure disorder.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00755040
- Testing
- cyclosporine ophthalmic emulsion
- Where
- 5 sites in United States
- Volunteers
- 164 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
EBV-T/NK LPD
Improved Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation Protocol for the Treatment of Epstein Barr Virus T/NK Lymphoproliferative Disease (EBV-T/NK LPD) and Prevention of Post Transplant Graft-versus-host Disease
To investigate whether the addition of recombinant humanized anti-CD25 monoclonal antibody to the conventional EBV-T/NK LPD conditioning regimen can prevent acute and chronic GVHD after transplantation, improve the severity of…
- Trial name
- NCT07029958
- Testing
- recombinant humanized anti-CD25 monoclonal antibody
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Beijing Children's Hospital
Plasma Cell Myeloma, Secondary Amyloidosis
Daratumumab After Stem Cell Transplant in Treating Patients With Multiple Myeloma
This phase II trial studies how well daratumumab after a stem cell transplant works in treating patients with multiple myeloma. Monoclonal antibodies, such as daratumumab, may kill cancer cells that are left after chemotherapy.
- Trial name
- NCT03346135
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Daratumumab, Laboratory Biomarker Analysis
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- City of Hope Medical Center
Monomorphic B-Cell Post-Transplant Lymphoproliferative Disorder, Polymorphic Post-Transplant Lymphoproliferative Disorder
Tafasitamab and Rituximab for Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder
This phase II trial tests how well tafasitamab and rituximab work for front-line treatment of patients with post-transplant lymphoproliferative disorder.
- Trial name
- NCT05786040
- Testing
- Biopsy, Biospecimen Collection, Computed Tomography
- Where
- 4 sites in United States
- Volunteers
- 28 people
- Sponsor
- Timothy Voorhees
Multiple Myeloma
Assessment of Molecular Remission by ASO-qPCR After Bortezomib-dexamethasone (Vel/Dex) Followed by ASCT
The primary objective of this study is to determine the rate of molecular remissions (MolR) assessed by ASO-RQ-PCR technique after induction treatment with bortezomib and dexamethasone (Vel/Dex) prior to high-dose therapy with…
- Trial name
- NCT00861250
- Testing
- bortezomib + dexamethasone
- Where
- Finland
- Volunteers
- 47 people
- Sponsor
- Tampere University Hospital